Your engineers are writing documents, not building your neurostimulator.

Your team is building a Class III neurostimulator. Fifteen engineers, eight months in. You just finished your first formal design review—and the consultant you brought in to assess DHF readiness found 47 gaps. Design inputs that reference user needs documents that don't exist yet. A risk analysis that hasn't been updated since the electrode geometry changed in sprint four. Verification protocols written against requirements that were revised three versions ago. The RA consultant who identified all this costs $350 an hour and can't come back until next month.

You know the engineering is solid. The device works. But the distance between "the device works" and "we can prove the device works in a format the FDA will accept" feels like six months of full-time documentation effort—and your PMA submission window is shrinking.

The cascade that breaks teams

It's never one thing—it's the cascade. Design inputs aren't traced to design outputs because the requirements evolved organically during development. The original specification said one thing; the device you built does something better, but nobody updated the spec. The risk analysis is a snapshot from month two, and the device has had four significant design changes since then—each introducing new failure modes that were discussed in engineering meetings but never formally captured. Your verification test protocols were written to demonstrate performance, not to satisfy specific design output requirements, so the traceability matrix has gaps that no amount of retroactive mapping can cleanly fill. Three engineers who made critical design decisions have since rotated to other projects, and their rationale lives in Slack threads and whiteboard photos.

This pattern repeats across 510(k), De Novo, and PMA programs. The regulatory pathway changes the evidence burden—a 510(k) needs a substantial equivalence argument, a De Novo needs proposed special controls, a PMA needs valid scientific evidence of safety and effectiveness—but the underlying failure mode is the same: the engineering was done right, and the documentation was done later.

The same team, with MANKAIND

Run the scenario again. Same team, same neurostimulator, same aggressive timeline. But from sprint one, engineering decisions flow into a structured record. When the lead mechanical engineer changes the electrode geometry, that decision propagates through the design history: affected design inputs are flagged for review, the risk analysis surfaces failure modes that need re-evaluation, and verification requirements update to reflect the new design output. The engineer made one decision. The platform handled the documentation cascade.

At the month-eight design review, the DHF isn't a reconstruction project—it's a current, structured reflection of every engineering decision made during development. The traceability matrix wasn't assembled after the fact; it was built as the decisions were made. The risk analysis isn't a stale snapshot; it evolved with the design. The rationale for that critical material selection in month three is captured in the engineering record, not locked in a departed engineer's memory.

For the 510(k) team down the hall, MANKAIND maps the predicate landscape and helps construct the substantial equivalence argument before the testing program begins—so bench tests generate the right data the first time, not data that needs supplementing after a deficiency letter. For the De Novo team upstairs, the platform structures the proposed special controls by analyzing what controls have been established for analogous device types.

The outcome

The design review at month eight finds four gaps instead of 47. The RA consultant spends her time on strategic questions—submission sequencing, pre-sub meeting strategy—instead of cataloging missing documents. The documentation phase that was supposed to take six months doesn't exist, because the documentation was generated continuously from the engineering work itself. The DHF is a living engineering record, not a deliverable assembled under deadline pressure by people reconstructing decisions they made months ago.

That is what engineering intelligence means in practice: a platform that makes the work of building a medical device visible, traceable, and defensible—so your team spends its time on engineering, not on proving that the engineering happened.